BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback